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Abstract 
Langerhans cell histiocytosis is a rare group
of  proliferative  disorders.  Beside  cutaneous
involvement,  other  internal  organs  can  be
affected. The treatment of cutaneous lesions is
difficult and relies on topical corticosteroids,
carmustine,  nitrogen  mustard,  and  pho-
tochemotherapy.  Systemic  steroids  and  vin-
blastine are used for recalcitrant skin lesions.
However, some cases fail to respond. An 18-
month  old  boy  presented  a  CD1a
+,  S100a
+
Langerhans  cell  histocytosis  with  cutaneous
and severe scalp involvement. Topical corticos-
teroids and nitrogen mustard failed to improve
the skin lesions. Systemic corticosteroids and
vinblastine improved the truncal involvement
but had no effect on the scalp lesions. Methyl-
aminolevulinate  (MAL)  based  photodynamic
therapy (PDT) resulted in a significant regres-
sion  of  the  scalp  lesions.  Control  histology
revealed an almost complete clearance of the
tumor  infiltrate.  Clinical  follow-up  after  six
months showed no recurrence. 
Although  spontaneous  regression  of  cuta-
neous  Langerhans  cell  histiocytosis  is
observed,  the  rapid  effect  of  photodynamic
therapy  after  several  failures  of  other  treat-
ment suggests that photodynamic therapy was
successful. As far as we know this is the first
report of photodynamic therapy for refractory
skin lesions. Larger series are needed to deter-
mine whether photodynamic therapy deserves
a place in the treatment of multiresistant cuta-
neous Langerhans cell histiocytosis.
Introduction
Langerhans  cell  histiocytosis  (LCH)  is  a
rare  group  of  proliferative  disorders.  The
prevalence is estimated between 1 and 2 per
1,000,000. The male:female ratio is 2:1. Usually
LCH  affects  young  children,  particularly
between the ages of one and three years. LCH
presents  an  oligoclonal  proliferation  of
Langerhans cells (LC). The etiology has not
been elucidated. LCH affects the skin in 40% of
the cases, but almost any other internal organ
may be involved.
1 The clinical expression and
the prognosis principally depend on the clini-
cal type and the number of organs affected.
2
First-line treatment for the cutaneous lesions
relies  on  topical  corticosteroids.  Topical
chemotherapy (nitrogen mustard, carmustine)
or  PUVA-therapy  are  interesting  second-line
options.  Systemic  chemotherapy  is  reserved
for  severe  and  refractory  cutaneous  involve-
ment. 
Notwithstanding, some cases fail to respond
and require alternative therapy. Photodynamic
therapy (PDT) is an FDA-recognized treatment
option  for  superficial  basal  cell  carcinoma,
Bowen’s disease and actinic keratosis.
3-6 The
preferential accumulation of the photosensi-
tizing agents in hypermetabolic cells (i.e. pre-
cancerous and cancerous cells) explains the
selectiveness of PDT. The spectrum of other
cutaneous  oncological  conditions  effectively
treated  by  PDT  is  continuously  increasing.
7
The presence of an oligoclonal proliferation of
LCs in LCH was the rationale for PDT treat-
ment. This paper reports the first successful
PDT  treatment  of  multi-resistant  scalp
Langerhans cell histiocytosis in a young boy. 
Case Report
An 18-month old boy visited the dermatology
department  for  erythematous  and  squamous
lesions of the trunk and the scalp. The lesions
appeared at the age of eight months and pro-
gressively spread over the trunk and scalp. A
pediatrician  proposed  a  diagnosis  of  atopic
dermatitis. The child was otherwise healthy,
did not take any medication and presented a
normal development. There were no signs of
growth  retardation.  There  was  no  particular
family medical history. 
Skin  examination  revealed  infiltrated,
sometimes purpuric, papular and slightly squa-
mous, ill-defined lesions on the trunk. These
lesions  were  neither  pruritic  nor  painful.
Severe  inflammatory  and  crusting  lesions
were evidenced on the scalp and behind the
ears  (Figure  1).  These  lesions  were  painful
and itchy, and the child used to scratch them.
Further  clinical  examination  was  unremark-
able. No adenopathies were evidenced. A cuta-
neous biopsy was performed under local anes-
thesia.  Histology  suggested  LCH.  Immuno  -
histochemical  staining  revealed  a  CD1a
+,
S100a
+ infiltrate with a proliferative KI67 frac-
tion of 15%, confirming the diagnosis of LCH.
Electron microscopy to ascertain the presence
of  Birbeck  granules  was  not  performed.  An
extensive  internal  workup,  including  ultra-
sound, blood sampling, chest radiography and
chest CT scan, was normal. The final diagnosis
was a cutaneous LCH (multifocal single organ
disease), according to the current classifica-
tion of histiocytic disorders.
2 The clinical score
for disease activity was 2 (clinical findings: 2,
laboratory evaluation: 0, radiological studies:
0).
2
No  regression  of  the  skin  lesions  was
observed following topical applications of very
potent  corticosteroids  (clobetasol  propionate
0.05% cream, Dermovate©, GSK), but the itch-
ing  sensations  were  partially  relieved.
Subsequent  treatment  with  topical  nitrogen
mustard (10 mg/50 mL H20, 3 times/week, for
three  weeks  (Mustargen©))  also  failed  to
improve the skin lesions. PUVA therapy was
not performed, as efficacy on the hairy scalp is
limited.  Systemic  corticosteroids  (40
mg/m²/day) also failed. Finally, following sys-
temic vinblastine (Velbe©), a partial regres-
sion of the truncal lesions was observed but
the aspect of the scalp lesions did not improve.
During the second chemotherapy course, fever
and  neutropenia  with  a  bilateral  interstitial
pneumopathy  suddenly  appeared,  necessitat-
ing interruption of treatment. The pulmonary
lesions resolved and four months later, a sub-
sequent treatment combining vinblastine and
corticosteroids (once every two weeks for six
months) was started. The truncal lesions pro-
gressively disappeared but the scalp and ear
lesions resisted. A new skin biopsy of the scalp
was performed, revealing S-100a
+ and CD1a
+
Langerhans cell histiocytosis. The KI67 growth
fraction was 5%. Finally, a methyl-aminolevuli-
nate (MAL)-based photodynamic therapy was
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performed under total anesthesia. Previously,
a cream containing 15% urea was applied once
daily for 15 days to diminish the hyperkeratot-
ic  character  of  the  scalp  lesions.  MAL
(Metvix© cream 5%, Galderma) was applied
under occlusion, using a plastic film, for three
hours.  Red  light  LED  illumination  was  per-
formed using an Aktilite© light source (634
nm,  74  J/cm
2)  for  eight  minutes.  Post-treat-
ment crusting was limited using an antibiotic
ointment  (mupiro  cine,  Bactroban©)  twice
daily for one week. The child did not complain
of any pain or itching after the treatment. No
painkillers  were  required.  Two  weeks  after
PDT treatment, a significant reduction of the
inflammation  and  crusting  was  noted.  Four
weeks  later,  there  was  an  almost  complete
healing (Figure 2). A control biopsy revealed a
complete histological clearing and only some
residual  CD1a
+ LC  on  immunohistological
examination. After a follow-up of six months
the scalp was still recurrence free.
Discussion
Langerhans  cell  histiocytosis  is  rarely
encountered and encompasses a group of dis-
orders characterized by the proliferation and
infiltration  of  Langerhans  cells,  potentially
affecting almost every organ.
2,8 The diagnosis
of cutaneous LCH is suggested by histopathol-
ogy and confirmed by a positive immunohisto-
chemical  signal  for  the  CD1a,  S100a  and
CD207  (Langerin)  antigens.
1,9 Electron
microscopy  evidences  the  pathognomical
intracytoplasmic Birbeck granules, but is not
routinely  performed.
1,9 The  skin  lesions  are
polymorphous, but macular, papular and vesic-
ular elements covered by slight brown crusts
are  characteristic  clinical  features.
9,10 The
usual localizations include the face, the front
and the scalp, the trunk and the large folds.
Bone disease usually affects one single bone
with pain, swelling, deformation, fracture, etc.
Cranial, mandibular, vertebral, and the pelvic
bones are the most frequently affected. Lung
disease typically presents as a reticulo-micron-
odular  syndrome  with  dyspnea,  a  dry  cough
and  fever.  Hematologic  disease  is  polymor-
phous and may evolve to pancytopenia. Other
signs, such as diabetes insipidia, hepatosple  -
nomegalia, sclerosing cholangitis, median oti-
tis may be observed.
Treatment  is  directed  towards  decreasing
the activity and proliferation of the histiocytes
and to relieve symptoms such as itching and
stinging,  as  well  as  to  improve  the  esthetic
aspects and quality of life.
11 As the prognosis of
isolated  cutaneous  involvement  is  favorable
and as auto-resolution may be expected, it is
recommended to start with the simplest treat-
ment and progress to systemic or intervention-
al therapy only if required. However, treatment
is recommended as isolated cutaneous LCH in
infants is not always a benign disorder and the
evolution is not always predictable.
10
Topical  corticosteroids  (potent  or  very
potent) are recommended as first-line treat-
ment.
2 Surgery may be considered for isolated
and  small  lesions.  When  these  fail,  topical
chemotherapy can be used: daily applications
of nitrogen mustard (0.02% mechlorethamine
hydrochloride, mustine), an alkylating cytosta-
tic  agent
12 often  bring  clinical  improvement
within  ten  days.
13 After  induction  treatment,
topical  chemotherapy  can  be  considered  as
maintenance  therapy.
14 Although  adverse
effects are minimal in the short-term, the pos-
sibility of long-term cutaneous carcinogenicity
is  not  excluded.
13 Carmustine  (bis-chloroni-
trosourea,  BCNU)  is  another  mustard  gas-
related  α-chloro-nitrosourea  compound  used
as  an  alkylating  agent  for  cutaneous  LCH.
15
New treatments include imiquimod, a topical
interferon-inducing agent. A case of LCH was
effectively  treated  with  topical  imiquimod,
resulting  in  clinical  and  histological  clear-
ance.
16 Oral 8-methoxypsoralen (8-MOP) plus
ultraviolet A (PUVA) therapy (3 times per week
for two months, 1-2 times per week mainte-
nance  PUVA)  is  an  interesting  treatment
option,  in  particular  offering  treatment  to
patients presenting extensive cutaneous dis-
ease.
17-19 Low-dose methotrexate (20 mg week-
ly)  successfully  treated  multiresistant  cuta-
neous LCH.
20,21 In some patients with multire-
sistant cutaneous LCH, subcutaneous interfer-
on-α2b achieved long remission periods.
15 Oral
thalidomide  (N-phtalimidoglutarimide,  200
mg/d) was effective for mucocutaneous LCH
after four weeks of treatment with total clear-
ing after three months. Maintenance therapy
using 100 mg/d can be recommended to pre-
vent  recurrent  disease.  Hence,  thalidomide
monotherapy represents an effective, safe and
well-tolerated  treatment  option  that  may  be
considered as first-line therapy for mucocuta-
neous LCH.
21-23 Systemic chemotherapy includ-
ing mercaptopurine and vinblastine, with or
without prednisone and/or methotrexate, may
be used in case of extensive internal disease.
19
Effective therapies for cases unresponsive to
the  above  include  cytosine  arabinoside  and
cladribine.  Intravenous  cladribine  (2-
chlorodeoxyadenosine, 2CDA), a purine ana-
log, has also been proven effective.
15 Emerging
therapies  include  monoclonal  antibodies
against the CD1a or CD52 epitopes found on
Langerhans cells. Although normal epidermal
Langerhans cells do not express CD52, patho-
logical  LCH  cells  express  CD52,  suggesting
that alemtuzumab may represent a new, tar-
geted therapy for LCH.
24
PDT  permits  selective  destruction  of  cells
accumulating the topical photosensitizer MAL
and subsequently activated by a light source.
7
Through  a  non-elucidated  selectivity  mecha-
nism, a ten-fold higher intracellular concentra-
tion  of  the  photosensitizer  is  achieved  in
metabolically  more  active  cells,  such  as  the
keratinocytes of actinic keratosis. This selec-
tivity is not only restricted to epithelial cells, as
endothelial cells, lymphocytes, as well as glan-
dular  cells  may  also  be  effectively  targeted,
hence expanding the therapeutic potential of
PDT.
7 This case furthermore suggests that the
LCH cells are capable of concentrating the pho-
tosensitizer, whereas the normal epidermal LC
are not affected. The rationale behind PDT for
LCH  was  the  selective  accumulation  of  the
photosensitizer  in  metabolically  more  active
cells. In our patient, the large area involved,
the pain inherent in the illumination phase
and the young age of the child, prompted us to
perform PDT under total anesthesia. As no pre-
vious experience is available on PDT in LCH, a
standard treatment procedure was chosen. It is
clear  that  specific  PDT  protocols  for  LCH
should be developed according to future clini-
cal experience. The child did not experience
any post-procedure pain and did not ask for
pain reducing medication. The time course of
the crusting was similar to superficial basal
cell carcinoma treatments. 
In summary, as far as we know, this case
presents the first successful PDT treatment of
multiresistant  cutaneous  LHC.  More  experi-
ence  should  be  gathered  to  determine  the
appropriate role of PDT in the management of
cutaneous LHC. 
Case Report
Figure  1.  Langerhans  cell  histiocytosis
involving the scalp.
Figure 2. Aspect of the scalp one month
after PDT. [page 96] [Rare Tumors 2010; 2:e34]
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